Abstract：Objective To explore the effect of percutaneous transhepatic biliary drainage (PTBD) in the treatment of hilar cholangiocarcinoma (HCCA). Methods A total of 82 patients with HCCA treated in our hospital from November 2017 to May 2019 were divided into a PTBD group and an endoscopic nasobiliary drainage (ENBD) group, with 41 cases in each group. The PTBD group was treated with PTBD and the ENBD group with ENBD. The 2-year survival rate, mean survival time, liver function indexes and complications before and after the treatment were compared between the two groups. Results After the treatment, the levels of TBIL, ALT and ALP in the PTBD group were (196.45±18.59) mol/L, (32.16±7.28) U/L, and (170.46±46.82) U/L respectively, which were lower than those in the ENBD group: (206.83±17.56) mol/L, (36.89±8.75) U/L, and (198.86±50.34) U/L respectively (t=2.599, 2.661, 2.645, P=0.011, 0.009, 0.010). There were no significant differences in TBIL levels between type I and type II patients before and after the treatment (t=1.318, 1.723, P=0.217, 0.095). After the treatment, the levels of TBIL in type III and type IV patients were (221.01±21.68) mol/L and (241.44±22.97) mol/L respectively, lower than those before the treatment: (262.35±25.47) mol/L and (301.49±28.53) mol/L respectively, and the differences were statistically significant (t=4.099, 4.637, both P<0.01). The mean survival time of the PTBD Group was months, which was significantly higher than that of the ENBD Group: months (χ2=23.514, P<0.01). Conclusion PTBD in the treatment of HCCA has the advantages of high drainage volume, high safety, less trauma and fewer complications. It is helpful to improve the liver function and prolong the survival time. It is worthy of popularization and application.
张燚. 经皮肝穿刺胆道引流术在肝门部胆管癌治疗中的应用研究[J]. 中国校医, 2022, 36(1): 35-37,40.
ZHANG Yi. Application of percutaneous transhepatic biliary drainage in treatment of hilar cholangiocarcinoma. Chinese Journal of School Doctor, 2022, 36(1): 35-37,40.
2022, Vol. 36 
